KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Research & Development (2016 - 2025)

Neogenomics (NEO) has disclosed Research & Development for 15 consecutive years, with $9.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development rose 15.18% year-over-year to $9.2 million, compared with a TTM value of $37.1 million through Dec 2025, up 18.99%, and an annual FY2025 reading of $37.1 million, up 18.99% over the prior year.
  • Research & Development was $9.2 million for Q4 2025 at Neogenomics, up from $8.7 million in the prior quarter.
  • Across five years, Research & Development topped out at $10.2 million in Q1 2025 and bottomed at $2.5 million in Q1 2021.
  • Average Research & Development over 5 years is $7.4 million, with a median of $7.7 million recorded in 2024.
  • The sharpest move saw Research & Development skyrocketed 305.38% in 2021, then dropped 27.72% in 2023.
  • Year by year, Research & Development stood at $8.5 million in 2021, then fell by 21.59% to $6.7 million in 2022, then grew by 6.77% to $7.1 million in 2023, then rose by 11.81% to $8.0 million in 2024, then rose by 15.18% to $9.2 million in 2025.
  • Business Quant data shows Research & Development for NEO at $9.2 million in Q4 2025, $8.7 million in Q3 2025, and $9.0 million in Q2 2025.